Paper Details

  1. Home
  2. Paper Details

[Chinese Expert Consensus on Management of Special Adverse Effects 
Associated with Lorlatinib].

Author: , FanYun, HongZhen, JiaFujun, LiGuanjun, LiJuan, LiYong, LiuZhe, LuShun, LuYou, WuYi-Long, ZhouJianying, ZhouQing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Lorlatinib is a third-generation ALK tyrosine kinase inhibitor with potent activity against various ALK mutations, including those resistant to crizotinib and second-generation inhibitors. The study discusses the efficacy and side effects of lorlatinib in treating advanced NSCLC with ALK positivity, emphasizing the need for careful patient evaluation and monitoring.
Paper Details　
Original Abstract of the Article :
Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411957/

データ提供：米国国立医学図書館（NLM）

Lorlatinib: A New Hope for ALK-Positive Lung Cancer

Anaplastic lymphoma kinase (ALK) fusions are a common type of mutation found in non-small cell lung cancer (NSCLC). Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) that has shown promising results in treating ALK-positive NSCLC. It's like discovering a hidden oasis in the vast desert of lung cancer treatment, offering new hope for patients.

Lorlatinib: A Powerful Weapon Against ALK-Positive Lung Cancer

This expert consensus provides guidance on the management of special adverse effects associated with lorlatinib. It emphasizes the importance of careful monitoring and management of potential side effects, such as hyperlipidemia and central nervous system effects, to ensure the safe and effective use of this potent medication. It's like navigating the treacherous landscape of potential side effects, seeking to minimize risks and maximize benefits for patients.

A Multidisciplinary Approach to Lung Cancer Treatment

The consensus highlights the need for a multidisciplinary approach to treating ALK-positive NSCLC. This involves collaboration between oncologists, pharmacists, and other healthcare professionals to develop comprehensive diagnostic and therapeutic strategies. It's like a caravan of experts working together to provide the best possible care for patients facing this challenging disease.

Dr.Camel's Conclusion

This expert consensus provides valuable guidance for managing the use of lorlatinib in patients with ALK-positive NSCLC. It underscores the importance of personalized treatment approaches, careful monitoring of potential side effects, and multidisciplinary collaboration to optimize patient outcomes.

Date :
  1. Date Completed 2022-08-26
  2. Date Revised 2022-09-13
Further Info :

Pubmed ID

36002192

DOI: Digital Object Identifier

PMC9411957

Related Literature

Article Analysis
・Side Effects of lorlatinib
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.